immucor posts
FeedPosted Apr 1st 2010 9:30AM by Trey Thoelcke (RSS feed)
Filed under: Earnings Reports
Wednesday after the closing bell, Norcross, Ga.-based Immucor Inc. (BLUD) reported a third-quarter net income of $20.1 million, or 28 cents per share, up from $19.5 million, or $0.27 per share, in the same quarter a year ago. Analysts polled by Thomson Reuters had expected earnings of $0.27 per share for the quarter, so this blood-test equipment maker manages to hang on to its streak of quarterly earnings beats.
Revenue for this quarter rose 7% from a year ago to $80.5 million, primarily due to price contributions and currency. But that fell just short of analysts' estimates of $80.9 million.
Continue reading Immucor EPS Inch Higher in Q3, Beat Expectations
Posted Sep 27th 2009 12:30PM by Trey Thoelcke (RSS feed)
Filed under: Earnings Reports, Forecasts, Darden Restaurants (DRI), NIKE, Inc'B' (NKE), Economic Data
Autumn has arrived and the quarter winds down this week. The Dow has been inching toward 10,000 for a while now, though it closed lower in the past three sessions. Can it make it to 10,000 for the start of the third quarter? If so, what will push it higher? If not, what will drag it down further?
Continue reading The week in preview: Is the rally over?
Posted Apr 11th 2009 11:40AM by Trey Thoelcke (RSS feed)
Filed under: Earnings Reports, Brinker Intl (EAT), Alcoa Inc (AA), Bed Bath and Beyond (BBBY), Family Dollar Stores (FDO), Research in Motion (RIMM), Morgan Stanley (MS), Wells Fargo (WFC)
Here are some highlights from this past week's earnings coverage from BloggingStocks:
Continue reading Earnings highlights: Family Dollar, Bed Bath & Beyond, Alcoa, Wells Fargo and more
Posted Feb 23rd 2009 2:00PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy, Recession, Obama Picks
Two leading growth stock expert, Brandon Clay, editor of Invest with an Edge, and Alexander Green, editor of The Oxford Club, turn to automated blood testing equipment maker Immucor (NASDAQ: BLUD) as a recession-resistant buy.
Clay suggest, "A good bet is to go with the strongest stock in that particular sector at the time of your pickThat way, the company you select at least has the momentum of the sector backing it. Typically the medical industry performs better than the overall market in a downturn. This recession has been no different.
"As we dug deeper into health care, one company surfaced that was worth our attention. Immucor is a blood testing equipment manufacturer specializing in pre-transfusion diagnostics.
"Established in 1982, they brought their first patent to market four years later. Since then they've become a leader in blood diagnostics and blood bank technology.
Continue reading Immucor (BLUD): Two experts bank on blood bank buy
Posted Apr 4th 2008 2:00PM by Larry Schutts (RSS feed)
Filed under: Earnings Reports, Technical Analysis, Stocks to Buy
Immucor (NASDAQ: BLUD) provides
automated systems used by hospitals, clinical laboratories and blood banks to detect and identify certain properties of the cell and serum components of human blood prior to transfusion. Products are primarily used to type blood and detect foreign antibodies. Immucor sells its systems and reagent tests directly in North America, Western Europe and Japan.
The company made news earlier in the week, when it reported Q3 EPS of 27 cents and revenues of $67.3 million. Analysts had been looking for 22 cents and $62.9 million. Management also guided FY08 EPS to at least 96 cents (92 cent consensus) and FY08 revenues to at least $257 million ($255.89M consensus).
Continue reading Immucor (BLUD): Shares define bullish 'flag' pattern